{"id":58222,"date":"2025-11-06T11:36:21","date_gmt":"2025-11-06T11:36:21","guid":{"rendered":"https:\/\/ibima.eu\/?page_id=58222"},"modified":"2025-11-21T08:45:38","modified_gmt":"2025-11-21T08:45:38","slug":"eup-ohamr-jtc-2026","status":"publish","type":"page","link":"https:\/\/ibima.eu\/en\/eup-ohamr-jtc-2026\/","title":{"rendered":"EUP OHAMR &#8211; JTC 2026"},"content":{"rendered":"<p>[et_pb_section fb_built=\u00bb1&#8243; admin_label=\u00bbsection\u00bb _builder_version=\u00bb4.25.1&#8243; custom_padding=\u00bb||0px|||\u00bb locked=\u00bboff\u00bb collapsed=\u00bboff\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_row column_structure=\u00bb1_5,3_5,1_5&#8243; _builder_version=\u00bb4.27.4&#8243; _module_preset=\u00bbdefault\u00bb custom_margin=\u00bb21px||||false|false\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_column type=\u00bb1_5&#8243; _builder_version=\u00bb4.25.1&#8243; _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][\/et_pb_column][et_pb_column type=\u00bb3_5&#8243; _builder_version=\u00bb4.25.1&#8243; _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_image src=\u00bbhttps:\/\/ibima.eu\/wp-content\/uploads\/2025\/11\/OHO-AMR-Logo.png\u00bb title_text=\u00bbOHO AMR Logo\u00bb align=\u00bbcenter\u00bb _builder_version=\u00bb4.27.4&#8243; _module_preset=\u00bbdefault\u00bb width=\u00bb54%\u00bb module_alignment=\u00bbcenter\u00bb custom_margin=\u00bb26px||||false|false\u00bb global_colors_info=\u00bb{}\u00bb][\/et_pb_image][\/et_pb_column][et_pb_column type=\u00bb1_5&#8243; _builder_version=\u00bb4.25.1&#8243; _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=\u00bb4.27.4&#8243; _module_preset=\u00bbdefault\u00bb custom_margin=\u00bb59px||||false|false\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_column type=\u00bb4_4&#8243; _builder_version=\u00bb4.25.1&#8243; _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_heading title=\u00bbEUP OHAMR \u2013 Joint Transnational Call 2026: Treatments and adherence to treatment protocols\u00bb _builder_version=\u00bb4.27.4&#8243; _module_preset=\u00bbdefault\u00bb title_text_align=\u00bbcenter\u00bb title_text_color=\u00bb#0C71C3&#8243; title_line_height=\u00bb1.3em\u00bb module_alignment=\u00bbcenter\u00bb global_colors_info=\u00bb{}\u00bb][\/et_pb_heading][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=\u00bb4.27.4&#8243; _module_preset=\u00bbdefault\u00bb width=\u00bb75.9%\u00bb custom_margin=\u00bb20px|auto||159px|false|false\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_column type=\u00bb4_4&#8243; _builder_version=\u00bb4.25.1&#8243; _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_text admin_label=\u00bbText\u00bb _builder_version=\u00bb4.27.4&#8243; header_text_color=\u00bb#000000&#8243; background_size=\u00bbinitial\u00bb background_position=\u00bbtop_left\u00bb background_repeat=\u00bbrepeat\u00bb width=\u00bb100%\u00bb custom_margin=\u00bb1px|-78px|||false|false\u00bb global_colors_info=\u00bb{}\u00bb]<\/p>\n<p data-start=\"407\" data-end=\"738\">La <strong data-start=\"410\" data-end=\"485\">European Partnership on One Health Antimicrobial Resistance (EUP OHAMR)<\/strong> ha lanzado la <strong data-start=\"522\" data-end=\"555\">Joint Transnational Call 2026<\/strong>, destinada a financiar proyectos de investigaci\u00f3n e innovaci\u00f3n centrados en el desarrollo de <strong data-start=\"649\" data-end=\"735\">nuevos tratamientos para hacer frente a la resistencia a los antimicrobianos (AMR)<\/strong>.<\/p>\n<p data-start=\"740\" data-end=\"1017\">La convocatoria financiar\u00e1 proyectos dedicados a desarrollar <strong data-start=\"635\" data-end=\"667\">nuevas opciones terap\u00e9uticas<\/strong> y <strong data-start=\"670\" data-end=\"717\">mejoras en la adherencia a los tratamientos<\/strong> para combatir la AMR bajo un enfoque One Health (salud humana, animal y vegetal).<\/p>\n<p>[\/et_pb_text][et_pb_heading title=\u00bbObjetivos principales\u00bb _builder_version=\u00bb4.27.4&#8243; _module_preset=\u00bbdefault\u00bb title_font=\u00bb|||on|||||\u00bb title_text_color=\u00bb#0C71C3&#8243; min_height=\u00bb0px\u00bb custom_margin=\u00bb20px||||false|false\u00bb global_colors_info=\u00bb{}\u00bb custom_padding__hover_enabled=\u00bbon|desktop\u00bb][\/et_pb_heading][\/et_pb_column][\/et_pb_row][et_pb_row admin_label=\u00bbrow\u00bb _builder_version=\u00bb4.25.1&#8243; background_size=\u00bbinitial\u00bb background_position=\u00bbtop_left\u00bb background_repeat=\u00bbrepeat\u00bb width=\u00bb77.1%\u00bb custom_margin=\u00bb|-259px||161px||\u00bb custom_padding=\u00bb|0px||9px||\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_column type=\u00bb4_4&#8243; _builder_version=\u00bb4.16&#8243; custom_padding=\u00bb|||\u00bb global_colors_info=\u00bb{}\u00bb custom_padding__hover=\u00bb|||\u00bb][et_pb_text admin_label=\u00bbText\u00bb _builder_version=\u00bb4.27.4&#8243; header_text_color=\u00bb#000000&#8243; background_size=\u00bbinitial\u00bb background_position=\u00bbtop_left\u00bb background_repeat=\u00bbrepeat\u00bb width=\u00bb100%\u00bb custom_margin=\u00bb11px|-78px|||false|false\u00bb global_colors_info=\u00bb{}\u00bb]<\/p>\n<p data-start=\"926\" data-end=\"1081\">Esta primera convocatoria de EUP OHAMR tiene como objetivo <strong data-start=\"1018\" data-end=\"1142\">mejorar las tasas de \u00e9xito terap\u00e9utico en pacientes, animales o plantas afectadas por infecciones bacterianas o f\u00fangicas<\/strong>, proporcionando nuevas opciones de tratamiento y reduciendo al mismo tiempo el riesgo de resistencia en los distintos entornos One Health.<\/p>\n<ul data-spread=\"false\" style=\"text-align: justify;\"><\/ul>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=\u00bb4.27.4&#8243; _module_preset=\u00bbdefault\u00bb width=\u00bb75.9%\u00bb custom_margin=\u00bb10px|auto||159px|false|false\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_column type=\u00bb4_4&#8243; _builder_version=\u00bb4.25.1&#8243; _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_heading title=\u00bbTopics de la convocatoria\u00bb _builder_version=\u00bb4.27.4&#8243; _module_preset=\u00bbdefault\u00bb title_font=\u00bb|||on|||||\u00bb title_text_color=\u00bb#0C71C3&#8243; min_height=\u00bb0px\u00bb custom_margin=\u00bb1px||||false|false\u00bb global_colors_info=\u00bb{}\u00bb custom_padding__hover_enabled=\u00bbon|desktop\u00bb][\/et_pb_heading][et_pb_text _builder_version=\u00bb4.27.4&#8243; _module_preset=\u00bbdefault\u00bb min_height=\u00bb88px\u00bb custom_padding=\u00bb||0px|11px||\u00bb global_colors_info=\u00bb{}\u00bb]<\/p>\n<p data-start=\"2073\" data-end=\"2141\">Las propuestas deber\u00e1n abordar <strong data-start=\"2104\" data-end=\"2140\">uno de los tres temas siguientes<\/strong>:<\/p>\n<ul>\n<li data-start=\"2143\" data-end=\"2363\"><strong data-start=\"2143\" data-end=\"2154\">Topic 1: <\/strong>\u00ab<em>Identify and develop new combination treatments using existing or innovative antimicrobials or antimicrobial with adjunctive treatments to extend drug efficacy and combat resistance\u00bb<\/em><strong data-start=\"2143\" data-end=\"2154\"><em>.<\/em><\/strong><\/li>\n<li data-start=\"2143\" data-end=\"2363\"><strong data-start=\"2365\" data-end=\"2376\">Topic 2.<\/strong> \u00ab<em>Develop tools and methods to improve adherence to treatment protocols\u00bb.<\/em><\/li>\n<li data-start=\"2143\" data-end=\"2363\"><strong data-start=\"2666\" data-end=\"2677\">Topic 3.<\/strong>\u00a0 \u00ab<em>Assess the impact of antimicrobials for veterinary and agricultural use on the risk of AMR transmission to humans and the environment to inform policies on the restriction of some antimicrobials for human use\u00bb.<\/em><\/li>\n<\/ul>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=\u00bb4.27.4&#8243; _module_preset=\u00bbdefault\u00bb width=\u00bb75.9%\u00bb custom_margin=\u00bb10px|auto||159px|false|false\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_column type=\u00bb4_4&#8243; _builder_version=\u00bb4.25.1&#8243; _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_heading title=\u00bbRequisitos comunes para todos los topics\u00bb _builder_version=\u00bb4.27.4&#8243; _module_preset=\u00bbdefault\u00bb title_font=\u00bb|||on|||||\u00bb title_text_color=\u00bb#0C71C3&#8243; min_height=\u00bb0px\u00bb custom_margin=\u00bb1px||||false|false\u00bb global_colors_info=\u00bb{}\u00bb custom_padding__hover_enabled=\u00bbon|desktop\u00bb][\/et_pb_heading][et_pb_text _builder_version=\u00bb4.27.4&#8243; _module_preset=\u00bbdefault\u00bb min_height=\u00bb88px\u00bb custom_padding=\u00bb||0px|11px||\u00bb global_colors_info=\u00bb{}\u00bb]<\/p>\n<p data-start=\"3092\" data-end=\"3114\">Los proyectos deber\u00e1n:<\/p>\n<ul data-start=\"3116\" data-end=\"3619\">\n<li data-start=\"3116\" data-end=\"3208\">\n<p data-start=\"3118\" data-end=\"3208\">Considerar el impacto en los distintos entornos One Health (humano\u2013animal\u2013medioambiental).<\/p>\n<\/li>\n<li data-start=\"3209\" data-end=\"3273\">\n<p data-start=\"3211\" data-end=\"3273\">Presentar <strong data-start=\"3221\" data-end=\"3244\">objetivos realistas<\/strong> y un plan de trabajo s\u00f3lido.<\/p>\n<\/li>\n<li data-start=\"3274\" data-end=\"3339\">\n<p data-start=\"3276\" data-end=\"3339\">Mostrar <strong data-start=\"3284\" data-end=\"3338\">potencial de impacto social, sanitario y econ\u00f3mico<\/strong>.<\/p>\n<\/li>\n<li data-start=\"3340\" data-end=\"3419\">\n<p data-start=\"3342\" data-end=\"3419\">Indicar la ruta para la adopci\u00f3n de resultados por parte de usuarios finales.<\/p>\n<\/li>\n<li data-start=\"3420\" data-end=\"3519\">\n<p data-start=\"3422\" data-end=\"3519\">Justificar la aportaci\u00f3n \u00fanica de cada socio y el valor a\u00f1adido de la colaboraci\u00f3n transnacional.<\/p>\n<\/li>\n<li data-start=\"3520\" data-end=\"3619\">\n<p data-start=\"3522\" data-end=\"3619\">Incluir, cuando sea pertinente, la participaci\u00f3n del sector privado (startups, PYMEs, industria).<\/p>\n<\/li>\n<\/ul>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=\u00bb4.27.4&#8243; _module_preset=\u00bbdefault\u00bb width=\u00bb75.9%\u00bb custom_margin=\u00bb14px|auto|-13px|159px|false|false\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_column type=\u00bb4_4&#8243; _builder_version=\u00bb4.25.1&#8243; _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_heading title=\u00bbCondiciones generales\u00bb _builder_version=\u00bb4.27.4&#8243; _module_preset=\u00bbdefault\u00bb title_font=\u00bb|||on|||||\u00bb title_text_color=\u00bb#0C71C3&#8243; min_height=\u00bb0px\u00bb custom_margin=\u00bb1px||||false|false\u00bb global_colors_info=\u00bb{}\u00bb custom_padding__hover_enabled=\u00bbon|desktop\u00bb][\/et_pb_heading][et_pb_text _builder_version=\u00bb4.27.4&#8243; _module_preset=\u00bbdefault\u00bb custom_padding=\u00bb||0px|11px||\u00bb global_colors_info=\u00bb{}\u00bb]<\/p>\n<ul>\n<li><strong>Pa\u00edses participantes<\/strong>: Austria, B\u00e9lgica, Canad\u00e1, Rep\u00fablica Checa, Dinamarca, Estonia, Finlandia, Francia, Alemania, Hungr\u00eda, Irlanda, Israel, Italia, Letonia, Lituania, Malta, Moldavia, Pa\u00edses Bajos, Noruega, Polonia, Portugal, Eslovaquia, Sud\u00e1frica, Espa\u00f1a, Suecia, Suiza, Turqu\u00eda, Reino Unido.<\/li>\n<li><strong>Compsici\u00f3n del Consorcio<\/strong>:\n<ul>\n<li>M\u00ednimo: 3 socios elegibles solicitando financiaci\u00f3n de 3 pa\u00edses diferentes<\/li>\n<li>M\u00e1ximo: 6 socios financiados y no financiados (hasta 7 si el consorcio incluye un pa\u00eds infrarepresentado, un <em data-start=\"3733\" data-end=\"3758\">Early-Career Researcher<\/em> o una PYME\/start-up\/entidad industrial)<\/li>\n<\/ul>\n<\/li>\n<li><strong data-start=\"3804\" data-end=\"3835\">Duraci\u00f3n: <\/strong>36 meses.<\/li>\n<li><strong data-start=\"3804\" data-end=\"3835\">Procedimiento en dos fases:<\/strong> Presentaci\u00f3n de <em data-start=\"3852\" data-end=\"3867\">pre-proposals<\/em> y <em data-start=\"3870\" data-end=\"3886\">full proposals<\/em>.<\/li>\n<li data-start=\"3890\" data-end=\"4119\"><strong>Definici\u00f3n<\/strong> <strong data-start=\"3892\" data-end=\"3940\">de Early-Career Researcher (ECR):<\/strong> Doctor\/a con un m\u00e1ximo de 8 a\u00f1os desde la obtenci\u00f3n del t\u00edtulo de doctorado, con posibilidad de extensi\u00f3n por interrupciones de carrera, permisos parentales o formaci\u00f3n m\u00e9dica.<\/li>\n<li><strong data-start=\"3363\" data-end=\"3380\">Financiaci\u00f3n:<\/strong> Cada socio ser\u00e1 financiado por su respectivo organismo nacional o regional.<\/li>\n<\/ul>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=\u00bb4.25.1&#8243; _module_preset=\u00bbdefault\u00bb width=\u00bb75.9%\u00bb custom_margin=\u00bb20px|auto||159px|false|false\u00bb locked=\u00bboff\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_column type=\u00bb4_4&#8243; _builder_version=\u00bb4.25.1&#8243; _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_heading title=\u00bbFinanciaci\u00f3n de la participaci\u00f3n de IBIMA\u00bb _builder_version=\u00bb4.27.4&#8243; _module_preset=\u00bbdefault\u00bb title_font=\u00bb|||on|||||\u00bb title_text_color=\u00bb#0C71C3&#8243; min_height=\u00bb0px\u00bb custom_margin=\u00bb1px||||false|false\u00bb global_colors_info=\u00bb{}\u00bb custom_padding__hover_enabled=\u00bbon|desktop\u00bb][\/et_pb_heading][et_pb_text _builder_version=\u00bb4.27.4&#8243; _module_preset=\u00bbdefault\u00bb custom_padding=\u00bb|||11px||\u00bb global_colors_info=\u00bb{}\u00bb]<\/p>\n<p>La financiaci\u00f3n se gestionar\u00e1 a trav\u00e9s del <strong>Instituto de Salud Carlos III<\/strong><\/p>\n<p><strong>Si se act\u00faa como coordinador:<\/strong><\/p>\n<ul>\n<li>300.000 \u20ac si hay <strong data-start=\"791\" data-end=\"817\">un \u00fanico socio espa\u00f1ol<\/strong> en la propuesta, actuando como coordinador.<\/li>\n<li data-start=\"411\" data-end=\"539\">400.000 \u20ac a repartir si hay <strong data-start=\"913\" data-end=\"943\">un socio espa\u00f1ol adicional<\/strong> en la propuesta y ambos solicitan financiaci\u00f3n del ISCIII.<\/li>\n<\/ul>\n<p><strong>Si se act\u00faa como socio:<\/strong><\/p>\n<ul>\n<li data-start=\"411\" data-end=\"539\">220.000 \u20ac (gastos generales incluidos), si hay <strong data-start=\"458\" data-end=\"484\">un \u00fanico socio espa\u00f1ol<\/strong> solicitando financiaci\u00f3n del ISCIII en la propuesta.<\/li>\n<li data-start=\"411\" data-end=\"539\">275.000 \u20ac (gastos generales incluidos), si hay <strong data-start=\"589\" data-end=\"613\">dos socios espa\u00f1oles<\/strong> solicitando financiaci\u00f3n del ISCIII en la propuesta.<\/li>\n<\/ul>\n<ul><\/ul>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=\u00bb4.27.4&#8243; _module_preset=\u00bbdefault\u00bb width=\u00bb75.9%\u00bb custom_margin=\u00bb10px|auto|0px|159px|false|false\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_column type=\u00bb4_4&#8243; _builder_version=\u00bb4.25.1&#8243; _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_heading title=\u00bbfechas clave\u00bb _builder_version=\u00bb4.27.4&#8243; _module_preset=\u00bbdefault\u00bb title_font=\u00bb|||on|||||\u00bb title_text_color=\u00bb#0C71C3&#8243; min_height=\u00bb0px\u00bb custom_margin=\u00bb1px||||false|false\u00bb global_colors_info=\u00bb{}\u00bb custom_padding__hover_enabled=\u00bbon|desktop\u00bb][\/et_pb_heading][et_pb_text _builder_version=\u00bb4.27.4&#8243; _module_preset=\u00bbdefault\u00bb custom_padding=\u00bb||0px|11px||\u00bb global_colors_info=\u00bb{}\u00bb]<\/p>\n<ul>\n<li data-start=\"52\" data-end=\"94\">\n<p data-start=\"54\" data-end=\"94\"><strong data-start=\"54\" data-end=\"80\">Apertura convocatoria:<\/strong> 18 Nov 2025<\/p>\n<\/li>\n<li data-start=\"95\" data-end=\"135\">\n<p data-start=\"97\" data-end=\"135\"><strong data-start=\"97\" data-end=\"121\">Webinar informativo:<\/strong> 26 Nov 2025<\/p>\n<\/li>\n<li data-start=\"136\" data-end=\"177\">\n<p data-start=\"138\" data-end=\"177\"><strong data-start=\"138\" data-end=\"164\">Cierre pre-propuestas:<\/strong> 2 Feb 2026<\/p>\n<\/li>\n<li data-start=\"178\" data-end=\"224\">\n<p data-start=\"180\" data-end=\"224\"><strong data-start=\"180\" data-end=\"210\">Resultados pre-propuestas:<\/strong> 29 Abr 2026<\/p>\n<\/li>\n<li data-start=\"225\" data-end=\"273\">\n<p data-start=\"227\" data-end=\"273\"><strong data-start=\"227\" data-end=\"259\">Cierre propuestas completas:<\/strong> 17 Jun 2026<\/p>\n<\/li>\n<li data-start=\"274\" data-end=\"314\">\n<p data-start=\"276\" data-end=\"314\"><strong data-start=\"276\" data-end=\"300\">Comunicaci\u00f3n de las evaluaciones:<\/strong> 30 Oct 2026<\/p>\n<\/li>\n<li data-start=\"315\" data-end=\"358\" data-is-last-node=\"\">\n<p data-start=\"317\" data-end=\"358\" data-is-last-node=\"\"><strong data-start=\"317\" data-end=\"338\">Inicio proyectos:<\/strong> Dic 2026 \u2013 Abr 2027<\/p>\n<\/li>\n<\/ul>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=\u00bb4.27.4&#8243; _module_preset=\u00bbdefault\u00bb width=\u00bb75.9%\u00bb custom_margin=\u00bb20px|auto|19px|159px|false|false\u00bb hover_enabled=\u00bb0&#8243; locked=\u00bboff\u00bb global_colors_info=\u00bb{}\u00bb sticky_enabled=\u00bb0&#8243;][et_pb_column type=\u00bb4_4&#8243; _builder_version=\u00bb4.25.1&#8243; _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_heading title=\u00bbDocumentaci\u00f3n y enlaces clave\u00bb _builder_version=\u00bb4.27.4&#8243; _module_preset=\u00bbdefault\u00bb title_font=\u00bb|||on|||||\u00bb title_text_color=\u00bb#0C71C3&#8243; min_height=\u00bb0px\u00bb custom_margin=\u00bb1px||||false|false\u00bb global_colors_info=\u00bb{}\u00bb custom_padding__hover_enabled=\u00bbon|desktop\u00bb][\/et_pb_heading][et_pb_text _builder_version=\u00bb4.27.4&#8243; _module_preset=\u00bbdefault\u00bb custom_padding=\u00bb|||11px||\u00bb global_colors_info=\u00bb{}\u00bb]<\/p>\n<ul>\n<li><a href=\"https:\/\/ohamr.eu\/calls\/call-2026-new-treatments-to-tackle-amr\/\">Web y texto de la convocatoria<\/a><\/li>\n<li><a href=\"https:\/\/ohamr.eu\/calls\/call-2026-new-treatments-to-tackle-amr\/jtc-2026-checklist-for-applicants\/\">Guidelines<\/a><\/li>\n<li><a href=\"https:\/\/sv-se.eu.invajo.com\/event\/eupohamr\/webinarforapplicants\">Registro Infoday<\/a><\/li>\n<li><a href=\"https:\/\/ptoutline.eu\/app\/OHAMR2026_OH-TREAT\">Plataforma de env\u00edo de propuestas<\/a><\/li>\n<li><a href=\"https:\/\/ohamr.eu\/app\/uploads\/2025\/11\/EUP-OHAMR-JTC-2026-Pre-proposal-template.docx\">Template de pre-propuesta<\/a><\/li>\n<li><a href=\"https:\/\/www2.ncn.gov.pl\/partners\/ohamr-2026\/\">Plataforma de matchmaking<\/a><\/li>\n<\/ul>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>La European Partnership on One Health Antimicrobial Resistance (EUP OHAMR) ha lanzado la Joint Transnational Call 2026, destinada a financiar proyectos de investigaci\u00f3n e innovaci\u00f3n centrados en el desarrollo de nuevos tratamientos para hacer frente a la resistencia a los antimicrobianos (AMR). La convocatoria financiar\u00e1 proyectos dedicados a desarrollar nuevas opciones terap\u00e9uticas y mejoras en [&hellip;]<\/p>\n","protected":false},"author":4,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"class_list":["post-58222","page","type-page","status-publish","hentry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>EUP OHAMR - JTC 2026 - Ibima<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ibima.eu\/en\/eup-ohamr-jtc-2026\/\" \/>\n<meta property=\"og:locale\" content=\"en_GB\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"EUP OHAMR - JTC 2026 - Ibima\" \/>\n<meta property=\"og:description\" content=\"La European Partnership on One Health Antimicrobial Resistance (EUP OHAMR) ha lanzado la Joint Transnational Call 2026, destinada a financiar proyectos de investigaci\u00f3n e innovaci\u00f3n centrados en el desarrollo de nuevos tratamientos para hacer frente a la resistencia a los antimicrobianos (AMR). La convocatoria financiar\u00e1 proyectos dedicados a desarrollar nuevas opciones terap\u00e9uticas y mejoras en [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ibima.eu\/en\/eup-ohamr-jtc-2026\/\" \/>\n<meta property=\"og:site_name\" content=\"Ibima\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-21T08:45:38+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Estimated reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/ibima.eu\\\/es\\\/eup-ohamr-jtc-2026\\\/\",\"url\":\"https:\\\/\\\/ibima.eu\\\/es\\\/eup-ohamr-jtc-2026\\\/\",\"name\":\"EUP OHAMR - JTC 2026 - Ibima\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/ibima.eu\\\/es\\\/#website\"},\"datePublished\":\"2025-11-06T11:36:21+00:00\",\"dateModified\":\"2025-11-21T08:45:38+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/ibima.eu\\\/es\\\/eup-ohamr-jtc-2026\\\/#breadcrumb\"},\"inLanguage\":\"en-GB\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/ibima.eu\\\/es\\\/eup-ohamr-jtc-2026\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/ibima.eu\\\/es\\\/eup-ohamr-jtc-2026\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Portada\",\"item\":\"https:\\\/\\\/ibima.eu\\\/es\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"EUP OHAMR &#8211; JTC 2026\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/ibima.eu\\\/es\\\/#website\",\"url\":\"https:\\\/\\\/ibima.eu\\\/es\\\/\",\"name\":\"Ibima\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/ibima.eu\\\/es\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-GB\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"EUP OHAMR - JTC 2026 - Ibima","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ibima.eu\/en\/eup-ohamr-jtc-2026\/","og_locale":"en_GB","og_type":"article","og_title":"EUP OHAMR - JTC 2026 - Ibima","og_description":"La European Partnership on One Health Antimicrobial Resistance (EUP OHAMR) ha lanzado la Joint Transnational Call 2026, destinada a financiar proyectos de investigaci\u00f3n e innovaci\u00f3n centrados en el desarrollo de nuevos tratamientos para hacer frente a la resistencia a los antimicrobianos (AMR). La convocatoria financiar\u00e1 proyectos dedicados a desarrollar nuevas opciones terap\u00e9uticas y mejoras en [&hellip;]","og_url":"https:\/\/ibima.eu\/en\/eup-ohamr-jtc-2026\/","og_site_name":"Ibima","article_modified_time":"2025-11-21T08:45:38+00:00","twitter_card":"summary_large_image","twitter_misc":{"Estimated reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/ibima.eu\/es\/eup-ohamr-jtc-2026\/","url":"https:\/\/ibima.eu\/es\/eup-ohamr-jtc-2026\/","name":"EUP OHAMR - JTC 2026 - Ibima","isPartOf":{"@id":"https:\/\/ibima.eu\/es\/#website"},"datePublished":"2025-11-06T11:36:21+00:00","dateModified":"2025-11-21T08:45:38+00:00","breadcrumb":{"@id":"https:\/\/ibima.eu\/es\/eup-ohamr-jtc-2026\/#breadcrumb"},"inLanguage":"en-GB","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ibima.eu\/es\/eup-ohamr-jtc-2026\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/ibima.eu\/es\/eup-ohamr-jtc-2026\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Portada","item":"https:\/\/ibima.eu\/es\/"},{"@type":"ListItem","position":2,"name":"EUP OHAMR &#8211; JTC 2026"}]},{"@type":"WebSite","@id":"https:\/\/ibima.eu\/es\/#website","url":"https:\/\/ibima.eu\/es\/","name":"Ibima","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ibima.eu\/es\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-GB"}]}},"_links":{"self":[{"href":"https:\/\/ibima.eu\/en\/wp-json\/wp\/v2\/pages\/58222","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ibima.eu\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/ibima.eu\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/ibima.eu\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/ibima.eu\/en\/wp-json\/wp\/v2\/comments?post=58222"}],"version-history":[{"count":12,"href":"https:\/\/ibima.eu\/en\/wp-json\/wp\/v2\/pages\/58222\/revisions"}],"predecessor-version":[{"id":58452,"href":"https:\/\/ibima.eu\/en\/wp-json\/wp\/v2\/pages\/58222\/revisions\/58452"}],"wp:attachment":[{"href":"https:\/\/ibima.eu\/en\/wp-json\/wp\/v2\/media?parent=58222"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}